LBXS2_May_2010_3__Press.jpg
2007
YEAR
110

Lonza and Bio*One Capital celebrated the groundbreaking of their second manufacturing facility in Singapore at the Tuas Biomedical Park. This was the second large-scale mammalian manufacturing plant in Singapore, and the third one globally that Lonza had built.

Lonza initiated large-scale production capacity and an innovative technology platform for an emerging product class: Antibody Drug Conjugates, (ADCs) which are utilized primarily in the treatment of cancer.

ADC isolater in Visp, Switzerland
ADC isolater in Visp, Switzerland